NON-INVASIVE PREDICTORS OF MAINTAINING REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH TOFACITINIB WHO DOSE-REDUCED FROM TOFACITINIB 10 MG TWICE DAILY TO 5 MG TWICE DAILY: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOMISED RIVETING STUDY

Geert R. D'Haens  1     Genoile O. Santana  2     William J. Sandborn  3     Irene Modesto  4     Chinyu Su  5     Nervin Lawendy  5     Jerome Paulissen  4     Marla C. Dubinsky  6     Miguel Regueiro     nicole kulisek     Sean Gardiner     Rajiv Mundayat     Joana Torres    
1 Amsterdam University Medical Centres,Amsterdam,Netherlands
2 University of the State of Bahia,Salvador,Brazil
3 University of California San Diego,La Jolla,United States
4 Pfizer Inc,New York,United States
5 Pfizer Inc,Collegeville,United States
6 Icahn School of M

Session
IBD (Posters)

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 1)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing